9.47

0.85% 0.08

Pre-market: 10.89 1.42 +14.99%

Assembly Biosciences Inc (ASMB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Assembly Biosciences Inc stock is traded at $9.47, with a volume of 16,140. It is up +0.85% in the last 24 hours and down -26.48% over the past month. Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Previous Close:

$9.39

Open:

$9.53

24h Volume:

16,140

Relative Volume:

0.57

Market Cap:

$71.06M

Revenue:

Net Income/Loss:

$-61.23M

P/E Ratio:

-0.7005

EPS:

-13.5194

Net Cash Flow:

$22.49M

1W Performance:

-12.40%

1M Performance:

-26.48%

6M Performance:

-35.36%

1Y Performance:

-29.85%

1-Day Range:

$9.30

$10.01

1-Week Range:

$9.04

$11.17

52-Week Range:

$9.04

$19.93

Assembly Biosciences Inc Stock (ASMB) Company Profile

Name

Assembly Biosciences Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

(833) 409-4583

Address

TWO TOWER PLACE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-12-06

Latest SEC Filings

ASMB's Discussions on Twitter

Compare ASMB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASMB Assembly Biosciences Inc	9.47	71.06M	0	-61.23M	22.49M	-13.52
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-25	Initiated	Guggenheim	Buy
Sep-20-24	Upgrade	Jefferies	Hold → Buy
Sep-13-21	Initiated	H.C. Wainwright	Neutral
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold
Oct-19-20	Initiated	Truist	Buy
Oct-16-19	Initiated	Mizuho	Buy
Nov-19-18	Initiated	Leerink Partners	Outperform
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy
Aug-08-18	Initiated	Robert W. Baird	Outperform
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral
Nov-08-17	Initiated	Jefferies	Buy
May-30-17	Initiated	Chardan Capital Markets	Buy

View All

Assembly Biosciences Inc Stock (ASMB) Latest News

Apr 01, 2025

Assembly Biosciences CEO sells shares worth $3,496 By Investing.com - Investing.com Canada

Apr 01, 2025

Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Mar 27, 2025

Research Analysts Offer Predictions for ASMB Q1 Earnings - Defense World

Mar 27, 2025

Mar 26, 2025

Research Analysts Issue Forecasts for ASMB FY2029 Earnings - Defense World

Mar 26, 2025

Assembly Biosciences (NASDAQ:ASMB) Now Covered by Guggenheim - Defense World

Mar 26, 2025

Assembly Biosciences Reports 2024 Financial Results and Progress - TipRanks

Mar 26, 2025

Mar 25, 2025

Guggenheim Initiates Coverage of Assembly Biosciences (ASMB) with Buy Recommendation - Nasdaq

Mar 25, 2025

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 25, 2025

Guggenheim Initiates Assembly Biosciences at Buy With $31 Price Target - MarketScreener

Mar 25, 2025

Assembly Biosciences (NASDAQ:ASMB) Lowered to Hold Rating by StockNews.com - Defense World

Mar 25, 2025

Assembly Biosciences (NASDAQ:ASMB) Receives “Neutral” Rating from HC Wainwright - Defense World

Mar 25, 2025

Mar 22, 2025

Assembly Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 22, 2025

Assembly Biosciences Inc Reports Annual EPS of -$6.69 and Revenue of $28.5 Million, Surpassing Estimates - GuruFocus

Mar 22, 2025

Mar 21, 2025

Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update - Defense World

Mar 21, 2025

Mar 20, 2025

Assembly Biosciences Inc Files For Mixed Shelf Offering Of Up To $250 Million -March 20, 2025 at 05:09 pm EDT - Marketscreener.com

Mar 20, 2025